TD Cowen bullish on 23andMe shares on Q4 revenue beat, strategic review

Must read

On Friday, shares of 23andMe Holding Co. (NASDAQ:ME) shares experienced an uptick in after-hours trading following the company’s announcement of fourth-quarter revenue that exceeded expectations.

The genetic testing and analysis firm also disclosed that a Special Committee, established on March 28, 2023, is in the process of evaluating strategic alternatives.

The company, known for its at-home DNA testing kits, has been contemplating a separation of its consumer-focused business from its research and therapeutics division.

This potential split is seen as a strategic move that could enhance the value of both segments of the business. The review by the Special Committee comes at a time when the company’s leadership is considering various options to maximize shareholder value.

Adding to the company’s news, the CEO of 23andMe publicly expressed an intention to take the company private on April 18, 2024. This announcement has contributed to the heightened interest in the company’s stock. However, the company has not provided any financial guidance in the wake of these developments.

TD Cowen, a firm providing financial services and analysis, has maintained a positive outlook on 23andMe. The firm’s analyst, supporting the stock’s potential, reiterated a Buy rating with a price target of $2.00.

The analyst’s stance reflects a belief that the ongoing strategic review and the consideration of a business split could potentially lead to increased shareholder value.

As the market processes these updates, investors are keeping a close watch on 23andMe’s strategic decisions and their implications for the company’s future.

The current review by the Special Committee and the CEO’s take-private intent are pivotal factors in the evolving narrative of 23andMe’s corporate trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

More articles

Latest article